Larrosa María Nieves, Canut-Blasco Andrés, Benito Natividad, Cantón Rafael, Cercenado Emilia, Docobo-Pérez Fernando, Fernández-Cuenca Felipe, Fernández-Domínguez Javier, Guinea Jesús, López-Navas Antonio, Moreno Miguel Ángel, Morosini Mª Isabel, Navarro Ferran, Martínez-Martínez Luis, Oliver Antonio
Servicio de Microbiología, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, Spain.
Servicio de Microbiología, Hospital Universitario de Álava, Vitoria, Spain.
Enferm Infecc Microbiol Clin (Engl Ed). 2023 Aug-Sep;41(7):430-435. doi: 10.1016/j.eimce.2022.09.002. Epub 2022 Sep 26.
The Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) presents in this document a series of recommendations intending to unify how cumulative antibiogram reports must be made in Clinical Microbiology Spanish laboratories. This article is based on the information included in the Clinical Microbiology Procedure No. 51, «Preparation of cumulative reports on antimicrobial susceptibility» of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), published in 2014. The recommendations also include the modifications in the definition of clinical interpretive categories recently published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in 2019. Its final objective is to establish a homogeneous way of preparing these summaries to compare results from different centers or aggregate the information from these in order to carry out an adequate local or even national surveillance regarding the evolution of antimicrobial susceptibility.
西班牙抗菌谱委员会(Comité Español del Antibiograma,COESANT)在本文件中提出了一系列建议,旨在统一西班牙临床微生物实验室累积抗菌谱报告的编制方式。本文基于西班牙传染病和临床微生物学会(SEIMC)2014年发布的第51号临床微生物学程序《抗菌药物敏感性累积报告的编制》中包含的信息。这些建议还包括欧洲抗菌药物敏感性测试委员会(EUCAST)2019年最近发布的临床解释类别定义的修改。其最终目标是建立一种编制这些总结的统一方法,以比较不同中心的结果或将这些信息汇总起来,以便对抗菌药物敏感性的演变进行充分的本地乃至全国性监测。